Skip to main content
Premium Trial:

Request an Annual Quote

Products & Services: Oct 15, 2009

Premium

Prometheus Laboratories has launched three microRNA-based diagnostics: ProOnc TumorSource Dx, ProOnc Squamous Dx, and ProOnc Mesothelioma Dx.

According to the company, the first identifies the tissue-of-origin of a metastatic tumor; the second classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers; and the third differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.

The tests were formerly known as miRview Mets, miRview Squamous, and miRview Meso, and were developed by Rosetta Genomics. In April, Rosetta agreed to license the US rights to the products to Prometheus (see RNAi News, 4/16/2009). The deal closed a few weeks later.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.